Figma Shares Indicated To Open $105/$110
Durham, NC-based biotech firm Humacyte, Inc. issued a statement on Monday addressing recent unspecified attacks, as disclosed in a regulatory filing with the Securities and Exchange Commission. The company, which specializes in biological products, provided the statement as Exhibit 99.1 in a Form 8-K filing dated April 17, 2025. Trading at $1.68, the stock has shown significant volatility recently, with InvestingPro data showing a 9.8% gain over the past week despite a steep 66.6% decline over six months.
According to the 8-K filing, the information relayed in the statement is not considered "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as explicitly referenced in such a filing. InvestingPro analysis reveals the company’s challenging financial position, with a current market capitalization of $260.6 million and an EBITDA of -$107.21 million in the last twelve months. Subscribers can access 12 additional ProTips and comprehensive financial metrics through InvestingPro’s detailed research reports.
Humacyte, previously known as Alpha Healthcare Acquisition Corp. before a name change on July 16, 2020, is incorporated in Delaware and has its executive offices on East North Carolina Highway 54 in Durham. The company’s common stock and redeemable warrants are listed on The Nasdaq Stock Market under the symbols HUMA and HUMAW, respectively. With a current ratio of 2.4, the company maintains adequate liquidity to meet its short-term obligations, though analysts project continued losses for the current fiscal year.
The firm is identified as an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
The specific nature of the attacks and the contents of Humacyte’s statement were not detailed in the 8-K filing summary. The full statement from Humacyte is included in the SEC filing as Exhibit 99.1.
This news is based on a press release statement and provides factual information without speculation on the significance or potential impact of the events described.
In other recent news, Humacyte reported a narrower fourth-quarter loss of $0.16 per share, surpassing analyst expectations of a $0.25 per share loss, but the company generated no revenue during the period. Despite receiving FDA approval for its vascular graft product, Symvess, in December, the commercial launch has not yet translated into revenue, although shipments to two Level 1 trauma centers began recently. For the full year 2024, Humacyte’s net loss widened to $148.7 million from $110.8 million in 2023, primarily due to increased research and development expenses and preparation costs for the commercial launch of Symvess. The company ended 2024 with $95.3 million in cash and equivalents and raised an additional $46.6 million through a public stock offering in March 2025.
In terms of analyst ratings, Benchmark maintained a Buy rating on Humacyte with a $17 price target, emphasizing the company’s potential in capturing market share for surgical procedures requiring vascular grafts. BTIG analyst Ryan Zimmerman also maintained a Buy rating but lowered the price target from $10 to $8, citing early commercial traction as evidence of the product’s potential. Humacyte plans to file an Investigational New Drug application in 2025 for coronary artery bypass grafting and aims to expand Symvess’ approved uses to include dialysis access by late 2026. CEO Laura Niklason expressed optimism about the product’s commercial launch, noting that 34 hospitals have initiated the approval process to purchase Symvess, with three having completed approvals. The company continues to focus on its strategic plans to enhance surgical outcomes and expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.